144061-16-5

Basic information

• Product Name: 2-(4-TRIFLUOROMETHYL-PHENYL)-THIAZOLE-4-CARBOXYLIC ACID
• Synonyms: CHEMBRDG-BB 4013405;2-[4-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOLE-4-CARBOXYLIC ACID;2-(4-TRIFLUOROMETHYL-PHENYL)-THIAZOLE-4-CARBOXYLIC ACID;2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-4-carboxylic acid(SALTDATA: 1.3H2O)
• CAS NO: 144061-16-5
• Molecular Formula: C₁₁H₆F₃NO₂S
• Molecular Weight: 273.23
• Mol File: 144061-16-5.mol

Chemical Properties

• Melting Point: 186 °C
• Boiling Point: 405.2 °C at 760 mmHg
• Flash Point: 198.9 °C
• Appearance: /
• Density: 1.489 g/cm³
• Vapor Pressure: 2.71E-07mmHg at 25°C
• Refractive Index: 1.558
• PKA: 3.33±0.10(Predicted)
• CAS DataBase Reference: 2-(4-TRIFLUOROMETHYL-PHENYL)-THIAZOLE-4-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-TRIFLUOROMETHYL-PHENYL)-THIAZOLE-4-CARBOXYLIC ACID(144061-16-5)
• EPA Substance Registry System: 2-(4-TRIFLUOROMETHYL-PHENYL)-THIAZOLE-4-CARBOXYLIC ACID(144061-16-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 144061-16-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-TRIFLUOROMETHYL-PHENYL)-THIAZOLE-4-CARBOXYLIC ACID is used as a synthetic intermediate for the development of new drugs, leveraging its unique structural features and biological activity to target various therapeutic areas.
Used in Agrochemical Industry:
In the agrochemical sector, 2-(4-TRIFLUOROMETHYL-PHENYL)-THIAZOLE-4-CARBOXYLIC ACID is employed as a precursor in the synthesis of novel pesticides and other crop protection agents, aiming to enhance crop yield and quality by combating pests and diseases.
It is crucial to handle 2-(4-TRIFLUOROMETHYL-PHENYL)-THIAZOLE-4-CARBOXYLIC ACID with caution and adhere to safety protocols, given its potential hazards as a chemical substance.

InChI:InChI=1/C11H6F3NO2S/c12-11(13,14)7-3-1-6(2-4-7)9-15-8(5-18-9)10(16)17/h1-5H,(H,16,17)

Upstream product

• 70-23-5 ethyl Bromopyruvate 
• 72505-21-6 4-trifluoromethylbenzthioamide 
• 175204-88-3 2-[4-(trifluoromethyl)phenyl]thiazole-4-carboxylic acid ethyl ester 
• 128796-39-4 4-trifluoromethylphenylboronic acid 

Downstream Products

• 857284-28-7 C₁₁H₅ClF₃NOS 

Relevant articles and documents

Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist

Farnesoid X receptor (FXR), a bile acid-activated nuclear receptor, regulates the metabolism of bile acid and lipids as well as maintains the stability of internal environment. FXR was considered as a therapeutic target of liver disorders, such as drug-induced liver injury, fatty liver and cholestasis. The previous reported FXR partial agonist 6 was a suitable lead compound in terms of its high potent and low molecular size, while the docking study of compound 6 suggested a large unoccupied hydrophobic pocket, which might be provided more possibility of structure-activity relationship (SAR) study. In this study, we have performed comprehensive SAR and molecular modeling studies based on lead compound 6. All of these efforts resulted in the identification of a novel series of FXR partial agonists. In this series, compound 41 revealed the best activity and strong interaction with binding pocket of FXR. Moreover, compound 41 protected mice against acetaminophen-induced hepatotoxicity by the regulation of FXR-related gene expression and improving antioxidant capacity. In summary, these results suggest that compound 41 is a promising FXR partial agonist suitable for further investigation.

Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor

Fibroblast activation protein (FAP) belongs to the family of prolyl-specific serine proteases and displays both exopeptidase and endopeptidase activities. FAP expression is undetectable in most normal adult tissues, but is greatly upregulated in sites of tissue remodeling, which include fibrosis, inflammation and cancer. Due to its restricted expression pattern and dual enzymatic activities, FAP inhibition is investigated as a therapeutic option for several diseases. In the present study, we described the structure–activity relationship of several synthesized compounds against DPPIV and prolyl oligopeptidase (PREP). In particular, BR102910 (compound 24) showed nanomolar potency and high selectivity. Moreover, the in vivo FAP inhibition study of BR102910 (compound 24) using C57BL/6J mice demonstrated exceptional profiles and satisfactory FAP inhibition efficacy. Based on excellent in vitro and in vivo profiles, the potential of BR102910 (compound 24) as a lead candidate for the treatment of type 2 diabetes is considered.